White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective

Publications
Category:
Published on:
April 20, 2022

What Qualifies as an NGT?

NGTs is a term for a range of new, leading-edge therapies that:

  • Expand science
    NGTs employ an expanding number of scientific approaches to diagnose and treat disease, including gene therapy, cell therapy, RNA therapy, immunotherapy, and hybrids of these therapeutic models
  • Meet the significant unmet need
    NGTs have secured approval by the EMA and/or FDA to meet significant unmet medical needs or promise significant improvement in patient health over current standards of care
  • Gain expedited market access
    NGTs are often approved through the FDA’s Breakthrough Therapy, EMA Prime Review, Rare Disease, and other priority review pathways—often after expedited reviews and clinical trials based on surrogate endpoints

About This White Paper 

This white paper explores NGTs, the market access and commercial challenges facing these innovations, solutions to those challenges, as well as patient and clinical ethical considerations.

Download this white paper to learn more about: 
  • Classification of Next Generation Therapies 
  • Challenges in access and commercialization of Next Generation Therapies, from clinical to access and commercialization challenges 
  • Innovative solutions for Next Generation Therapies access 
  • Patients’ view and ethical concerns 

Related news

Events January 27, 2023
Alira Health and Biocat Startup Support Program Presentation
Biocat and Alira Health partnered to foster Market Access for startups. Alira Health, a global healthcare advisory and technology company, and Biocat, a strategic stakeholder building(...)
Market Access Startups
Publications January 20, 2023
Insights on Market Access
To get her perspective on market access and what to expect in 2023, we spoke with Nerea Blanqué, Senior Vice President of Market Access and Pricing at Alira Health.
Market Access Medical Devices Pharma
Publications December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
News November 15, 2022
Alira Health Partners with Policy Matters to Foster Market Access in the UK
Alira Health, a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, announces its partnership with leading UK market access specialist(...)
Digital Health Healthcare Consulting Market Access
News November 10, 2022
Alira Health and GDMH together to boost Life Sciences innovation
The companies join forces for collaborative research and co-development of projects in the fields of Digital Health, Real-World Evidence and Market Access.
Clinical Trials Digital Health DTx Market Access Real-World Evidence RWE
Events October 7, 2022
Debate Sobre los IPT en Oncología
We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.
Market Access Product Development Regulatory
Publications October 5, 2022
Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain
Discover how companies’ target prices are impacted by the different variables leveraged during the P&R process for oncology and oncohematology’s first indication.
Market Access Oncology Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.